US2023364092A1PendingUtilityA1
Solid forms of a toll-like receptor modulator
Est. expiryApr 17, 2039(~12.7 yrs left)· nominal 20-yr term from priority
C07B 2200/13C07C 309/04C07C 59/255C07C 57/145C07C 57/15A61K 31/519A61K 31/7072A61K 31/522C07D 471/04A61K 45/06A61K 31/675A61P 31/20
59
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present disclosure provides crystalline forms, solvates and hydrates of (R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol, and methods of making.
Claims
exact text as granted — not AI-modified1 .- 13 . (canceled)
14 . A crystalline form of (R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol hydrochloride:
characterized by an XRPD pattern comprising four more peaks at 6.1°, 12.2°, 15.0°, 17.3°, 17.8°, 18.9°, 20.3°, 23.2°, or 24.1° 2θ (±0.2° 2θ), hydrochloride salt Form I.
15 . (canceled)
16 . The crystalline form of claim 14 , characterized by an XRPD pattern comprising peaks at 6.1°, 15.0°, and 17.8° 2θ (±0.2° 2θ).
17 . The crystalline form of claim 16 , wherein the XRPD pattern further comprises one or more additional peaks at 12.2°, 17.3°, 18.9°, 20.3°, 23.2°, or 24.1° 2θ (±0.2° 2θ).
18 . The crystalline form of claim 16 , wherein the XRPD pattern further comprises two or more additional peaks at 12.2°, 17.3°, 18.9°, 20.3°, 23.2°, or 24.1° 2θ (±0.2° 2θ).
19 . The crystalline form of claim 14 , characterized by an XRPD pattern comprising peaks at 12.2°, 18.9°, and 24.1° 2θ (±0.2° 2θ).
20 . The crystalline form of claim 19 , wherein the XRPD pattern further comprises one or more additional peaks at 6.1°, 15.0°, 17.3°, 17.8°, 20.3° and 23.2° 2θ (±0.2° 2θ).
21 . The crystalline form of claim 19 , wherein the XRPD pattern further comprises two or more additional peaks at 6.1°, 15.0°, 17.3°, 17.8°, 20.3° and 23.2° 2θ (±0.2° 2θ).
22 . The crystalline form of claim 14 , characterized by an XRPD pattern comprising peaks at 6.1°, 12.2°, 15.0°, 17.3°, 17.8°, 18.9°, 20.3°, 23.2°, and 24.1° 2θ (±0.2° 2θ).
23 . The crystalline form of claim 14 , characterized by an XRPD pattern substantially as shown in FIG. 5 .
24 . The crystalline form of claim 14 , characterized by a differential scanning calorimetry (DSC) thermogram having an endotherm with an onset of about 135° C.
25 . The crystalline form of claim 14 , characterized by a DSC thermogram substantially as shown in FIG. 6 .
26 . A crystalline form of (R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol hydrochloride:
characterized by an XRPD pattern comprising four or more peaks at 7.1°, 9.7°, 14.3°, 15.3°, 16.1°, 19.1°, 22.5°, 24.0°, or 26.0° 2θ (±0.2° 2θ), hydrochloride salt Form II.
27 . (canceled)
28 . The crystalline form of claim 26 , characterized by an XRPD pattern comprising peaks at 7.1°, 15.3°, and 24.0° 2θ (±0.2° 2θ).
29 . The crystalline form of claim 28 , wherein the XRPD pattern further comprises one or more additional peaks at 9.7°, 14.3°, 16.1°, 19.1°, 22.5°, or 26.0° 2θ (±0.2° 2θ).
30 . The crystalline form of claim 28 , wherein the XRPD pattern further comprises two or more additional peaks at 9.7°, 14.3°, 16.1°, 19.1°, 22.5°, or 26.0° 2θ (±0.2° 2θ).
31 . The crystalline form of claim 26 , characterized by an XRPD pattern comprising peaks at 14.3°, 16.1°, and 26.0° 2θ (±0.2° 2θ).
32 . The crystalline form of claim 31 , wherein the XRPD pattern further comprises one or more additional peaks at 7.1°, 9.7°, 15.3°, 19.1°, 22.5°, or 24.0° 2θ (±0.2° 2θ).
33 . The crystalline form of claim 31 , wherein the XRPD pattern further comprises two or more additional peaks at 7.1°, 9.7°, 15.3°, 19.1°, 22.5°, or 24.0° 2θ (±0.2° 2θ).
34 . The crystalline form of claim 31 , characterized by an XRPD pattern comprising peaks at 7.1°, 9.7°, 14.3°, 15.3°, 16.1°, 19.1°, 22.5°, 24.0°, and 26.0° 2θ (±0.2° 2θ).
35 . The crystalline form of claim 26 , characterized by an XRPD pattern substantially as shown in FIG. 9 .
36 . The crystalline form of claim 26 , characterized by a differential scanning calorimetry (DSC) thermogram having an endotherm with an onset of about 58° C.
37 . The crystalline form of claim 26 , characterized by a DSC thermogram substantially as shown in FIG. 10 .
38 .- 121 . (canceled)Join the waitlist — get patent alerts
Track US2023364092A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.